Herman Krapf

Eribis Pharmaceuticals AB, ('Eribis') was founded by Erik Bissessar and co-founded by Herman Krapf. Karolinska Development is the primary investing partner. The basis of Eribis is the Company's unique competence in developing peptides for the pharmacological use for treatment of several clinical indications. The company's main focus is on developing new, effective and safe drugs for the treatment of cardiovascular disorders, in particular acute myocardial ischemia, and also for surgical preconditioning. The Company is based on research in the fields of peptide chemistry and pharmacology. The main goal for Eribis is to develop its Candidate Drug to meet the market's demand for new and improved treatment in the field of cardio-protection. Other medical indications may be considered at a later stage.

Part of Sotera Health Co., Helax AB is a Swedish company that provides products for radiation-based cancer treatment. The company is based in Uppsala, Sweden. The company was founded by Hans Erik Dahlin. Helax was acquired by Nordion (Canada), Inc., part of Sotera Health Co. from July 30, 2018 on May 04, 1999.